Chimerix (CMRX) shares were up over 237% in recent trading Tuesday a day after the company said it plans to submit a new drug application with the US Food and Drug Administration seeking accelerated approval for dordaviprone.
The application covers approval for dordaviprone as a treatment for recurrent H3 K27M-mutant diffuse glioma, a rare and aggressive type of brain tumor that primarily affects children and young adults.
The company said it will request a priority review of the NDA and that a potential initial Prescription Drug User Fee Act action date for accelerated approval could come in Q3 2025.
Price: 2.92, Change: +2.06, Percent Change: +237.57
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。